Monitoring of erlotinib in pancreatic cancer patients during long-time administration and comparison to a physiologically based pharmacokinetic model.
Andrea GruberMartin CzejkaPhilipp BuchnerMarie KitzmuellerNairi Kirchbaumer BaroianChristian DittrichAzra Sahmanovic HrgovcicPublished in: Cancer chemotherapy and pharmacology (2018)
This study presents the approach of combining TDM and PBPK modeling for erlotinib, a drug with a high interaction potential. TDM is an important method to monitor drugs with increased inter-patient variability, additionally, the PBPK model contributed valuable insights to the interaction mechanisms involved, resulting in an effective combination from a PK perspective to ensure a safe treatment.